Oncopeptides secures Slovenia list price for Pepaxti, marking first Central and Eastern Europe expansion step

• Oncopeptides secured an official list price for Pepaxti in Slovenia, its first concrete expansion step into Central and Eastern Europe.
• The Slovenian medicines agency endorsed a Maximum Allowed Price, clearing a prerequisite for reimbursement talks with the national health insurer.
• Slovenia’s reference-pricing role across the region positions the move to support wider market-access efforts in Central and Eastern Europe.
• The list price became publicly available in Slovenia’s central medicines database on Aug. 15, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncopeptides AB published the original content used to generate this news brief on August 17, 2026, and is solely responsible for the information contained therein.